LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

9.47 0.64

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.41

Max

9.93

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.9M -81M
Verkoop	-3.4M 17M
Winstmarge	-467.23
Werknemers	260
EBITDA	-12M -86M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+198.62% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	66M 821M
Vorige openingsprijs	8.83
Vorige sluitingsprijs	9.47

Nieuwssentiment

By Acuity

40%

60%

113 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

5.575 / 6.6 Steun & Weerstand

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 mei 2026, 22:15 UTC

Acquisities, Fusies, Overnames

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mei 2026, 23:46 UTC

Marktinformatie

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mei 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mei 2026, 23:33 UTC

Marktinformatie

Gold Rises on Possible Position Adjustments -- Market Talk

11 mei 2026, 22:37 UTC

Marktinformatie

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mei 2026, 22:32 UTC

Winsten

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mei 2026, 22:02 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mei 2026, 21:49 UTC

Winsten

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mei 2026, 21:42 UTC

Marktinformatie

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mei 2026, 21:23 UTC

Acquisities, Fusies, Overnames

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mei 2026, 21:12 UTC

Winsten

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mei 2026, 21:12 UTC

Winsten

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

11 mei 2026, 20:44 UTC

Winsten

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mei 2026, 20:43 UTC

Winsten

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Rev $136.4M >CLSK

11 mei 2026, 20:30 UTC

Winsten

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Cont Ops EPS $2.24 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Rev $1.6B >STE

11 mei 2026, 20:30 UTC

Winsten

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Adj EPS $2.83 >STE

11 mei 2026, 20:22 UTC

Populaire aandelen

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mei 2026, 19:37 UTC

Winsten

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mei 2026, 19:32 UTC

Marktinformatie

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

198.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.13 USD 198.62%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

113 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.